2025 Q4 -tulosraportti
40 päivää sitten
‧1 t 3 min
0,0723 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 28.1. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 | ||
2024 Q4 -tulosraportti 29.1.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·5.3.Teva's latest agreement with Blackstone life sciences can, in my view, mean the initiation of 4 new indications with anti-TL1A. This will mean 400mio us dollars in milestone payments from Sanofi whereby Teva can come with a nice upward revision. See page 18 for phase trials where it is stipulated that further trials "TBD" and page 68 states that the first four phase trials yield 100mio us dollar per phase trial in the Q4 report: 2025https://s24.q4cdn.com/720828402/files/doc_financials/2025/q4/28/Q4-2025-Earnings-Presentation.pdf It is my subjective opinion and not a recommendation to buy or sell·5.3.Basically, I believe that the 400mio US dollars are to cover Teva's development costs, and thereby the milestone payment will go straight to the bottom line.- ·21.2.
·17.2. · MuokattuDruckenmiller has reduced his exposure in TEVA from Q3 2025 to Q4 2025: Q3 16,593,935 Shares and Q4 5,874,870 shares. Thus a reduction of 10,719,065 shares or 65%. He thus owned as of 31/12-25 5874870 TEVA shares. He has probably exited around the top of Elliot Wave III around the top of the price channel at the time when the momentum indicators PMO and RSI(14) were overbought. We are probably facing a corrective wave IV, which is unlikely to be as deep and severe as corrective wave II, which we saw from January to April 2025. But note that today's price movement in TEVA on the good news could not sustain the strong upward movement throughout the day's trading. The TEVA stock seems a bit tired now, and needs time to recover, but the company TEVA is in good shape. I believe Druckenmiller wanted to take some risk off the table. No one knows how deep a correction wave IV will be. But after wave IV, wave V will come, which is an impulsive wave in the direction of the main trend, namely upwards. Here is the chart: https://schrts.co/XpuFTGbR·1.3.@WilliamBlake. Thanks for a good and interesting link. I am now completely convinced that SD has also paid close attention to Elliott Wave analysis. He has always used technical analysis.- He has probably sold 65% of his Teva shares around price 32 (without me being able to know that). If he bought at price 16 (after the meeting with Teva's management) and sold 65% at price 32 (and the completion of wave III), then the last 35% are practically his "free ride" up into wave V and the ultimate top in Teva. It will be exciting to follow his Teva dispositions going forward.
·17.2.Teva/Sanofi - Duvakitung - Phase 2B data shows robust data, so I believe the price will go up, 3-5% will not surprise me. "In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tolerated and safety was consistent with the induction study Findings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD". Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data.. This is one of my Teva price triggers that I can check off, and if it goes all the way to the end, it's a Blockbuster candidate as I see it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
40 päivää sitten
‧1 t 3 min
0,0723 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5.3.Teva's latest agreement with Blackstone life sciences can, in my view, mean the initiation of 4 new indications with anti-TL1A. This will mean 400mio us dollars in milestone payments from Sanofi whereby Teva can come with a nice upward revision. See page 18 for phase trials where it is stipulated that further trials "TBD" and page 68 states that the first four phase trials yield 100mio us dollar per phase trial in the Q4 report: 2025https://s24.q4cdn.com/720828402/files/doc_financials/2025/q4/28/Q4-2025-Earnings-Presentation.pdf It is my subjective opinion and not a recommendation to buy or sell·5.3.Basically, I believe that the 400mio US dollars are to cover Teva's development costs, and thereby the milestone payment will go straight to the bottom line.
- ·21.2.
- ·17.2. · MuokattuDruckenmiller has reduced his exposure in TEVA from Q3 2025 to Q4 2025: Q3 16,593,935 Shares and Q4 5,874,870 shares. Thus a reduction of 10,719,065 shares or 65%. He thus owned as of 31/12-25 5874870 TEVA shares. He has probably exited around the top of Elliot Wave III around the top of the price channel at the time when the momentum indicators PMO and RSI(14) were overbought. We are probably facing a corrective wave IV, which is unlikely to be as deep and severe as corrective wave II, which we saw from January to April 2025. But note that today's price movement in TEVA on the good news could not sustain the strong upward movement throughout the day's trading. The TEVA stock seems a bit tired now, and needs time to recover, but the company TEVA is in good shape. I believe Druckenmiller wanted to take some risk off the table. No one knows how deep a correction wave IV will be. But after wave IV, wave V will come, which is an impulsive wave in the direction of the main trend, namely upwards. Here is the chart: https://schrts.co/XpuFTGbR·1.3.@WilliamBlake. Thanks for a good and interesting link. I am now completely convinced that SD has also paid close attention to Elliott Wave analysis. He has always used technical analysis.- He has probably sold 65% of his Teva shares around price 32 (without me being able to know that). If he bought at price 16 (after the meeting with Teva's management) and sold 65% at price 32 (and the completion of wave III), then the last 35% are practically his "free ride" up into wave V and the ultimate top in Teva. It will be exciting to follow his Teva dispositions going forward.
- ·17.2.Teva/Sanofi - Duvakitung - Phase 2B data shows robust data, so I believe the price will go up, 3-5% will not surprise me. "In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tolerated and safety was consistent with the induction study Findings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD". Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data.. This is one of my Teva price triggers that I can check off, and if it goes all the way to the end, it's a Blockbuster candidate as I see it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 28.1. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 | ||
2024 Q4 -tulosraportti 29.1.2025 |
2025 Q4 -tulosraportti
40 päivää sitten
‧1 t 3 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 28.1. | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 7.5.2025 | ||
2024 Q4 -tulosraportti 29.1.2025 |
0,0723 USD/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5.3.Teva's latest agreement with Blackstone life sciences can, in my view, mean the initiation of 4 new indications with anti-TL1A. This will mean 400mio us dollars in milestone payments from Sanofi whereby Teva can come with a nice upward revision. See page 18 for phase trials where it is stipulated that further trials "TBD" and page 68 states that the first four phase trials yield 100mio us dollar per phase trial in the Q4 report: 2025https://s24.q4cdn.com/720828402/files/doc_financials/2025/q4/28/Q4-2025-Earnings-Presentation.pdf It is my subjective opinion and not a recommendation to buy or sell·5.3.Basically, I believe that the 400mio US dollars are to cover Teva's development costs, and thereby the milestone payment will go straight to the bottom line.
- ·21.2.
- ·17.2. · MuokattuDruckenmiller has reduced his exposure in TEVA from Q3 2025 to Q4 2025: Q3 16,593,935 Shares and Q4 5,874,870 shares. Thus a reduction of 10,719,065 shares or 65%. He thus owned as of 31/12-25 5874870 TEVA shares. He has probably exited around the top of Elliot Wave III around the top of the price channel at the time when the momentum indicators PMO and RSI(14) were overbought. We are probably facing a corrective wave IV, which is unlikely to be as deep and severe as corrective wave II, which we saw from January to April 2025. But note that today's price movement in TEVA on the good news could not sustain the strong upward movement throughout the day's trading. The TEVA stock seems a bit tired now, and needs time to recover, but the company TEVA is in good shape. I believe Druckenmiller wanted to take some risk off the table. No one knows how deep a correction wave IV will be. But after wave IV, wave V will come, which is an impulsive wave in the direction of the main trend, namely upwards. Here is the chart: https://schrts.co/XpuFTGbR·1.3.@WilliamBlake. Thanks for a good and interesting link. I am now completely convinced that SD has also paid close attention to Elliott Wave analysis. He has always used technical analysis.- He has probably sold 65% of his Teva shares around price 32 (without me being able to know that). If he bought at price 16 (after the meeting with Teva's management) and sold 65% at price 32 (and the completion of wave III), then the last 35% are practically his "free ride" up into wave V and the ultimate top in Teva. It will be exciting to follow his Teva dispositions going forward.
- ·17.2.Teva/Sanofi - Duvakitung - Phase 2B data shows robust data, so I believe the price will go up, 3-5% will not surprise me. "In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tolerated and safety was consistent with the induction study Findings reinforce the potential of duvakitug which is in ongoing phase 3 programs in UC and CD". Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data.. This is one of my Teva price triggers that I can check off, and if it goes all the way to the end, it's a Blockbuster candidate as I see it.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt